Drugs News and Research

RSS

Causes, prevention, and management of inferior alveolar nerve injury during implant dentistry

Although implant dentistry has become widely accepted to restore esthetics and function of teeth, it is not without risks. One serious complication that can occur is alteration of sensation due to nerve injury. Some reports place this occurrence as high as 13%. For dental practitioners, thorough understanding of anatomy, surgical procedures, and implant systems along with proper planning of treatment are essential to reduce this complication.

28 Oct 2010

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).

28 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

More effective therapeutic exercises underutilized in treatment of chronic neck pain

Duke University and University of North Carolina (UNC) researchers report in the November issue of Arthritis Care & Research that narcotics and diagnostic testing are overused in treating chronic neck pain. Their findings indicate clinicians may overlook more effective treatments for neck pain, such as therapeutic exercise. According to reviews cited in the study, evidence to support the effectiveness of therapeutic exercise in treating chronic neck pain is good, yet only 53% of subjects were prescribed such exercise.

28 Oct 2010

InVivo Therapeutics completes reverse merger with InVivo

InVivo Therapeutics Corporation a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp.

28 Oct 2010

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it received approval from the State Food and Drug Administration ("SFDA") Ethics Committee to commence Phase I human clinical trials of R-Bambuterol Hydrochloride, the Company's proprietary drug candidate for the treatment of asthma.

28 Oct 2010

£600 million cancer drug fund for UK cancer patients

Good news for cancer patients in England, the government has announced that it would fulfill a pledge to set up a drugs fund. Earlier the Department of Health promised the extra funding after a report revealed the low level of spending in the UK on cancer medication compared to the rest of Europe.

27 Oct 2010

US FDA cracks down on importation of unapproved new drugs for personal use

The United States Food and Drug Administration (“FDA”) is cracking down on the importation of unapproved new drugs with regards to personal use. Import Alert #66-41, “Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.” (“IA 66-41”) was most recently published on September 23, 2010. IA 66-41 contains a Red List, a list of importers whose products are automatically detained for FDA violations, of over 400 firms on the charge of importing misbranded unapproved new drugs. Benjamin England, founder of FDAImports.com, LLC and former FDA Compliance Officer, attorney, and Food and Drug Law expert states that “This Import Alert has been expanded to include importers and products of drugs imported strictly for personal use rather than just targeting foreign shippers, which is FDA's normal M.O.”

27 Oct 2010

Sharps Compliance first quarter retail billings increase 22% to record $1.9 million

Sharps Compliance Corp., a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications generated outside the hospital and large healthcare facility setting, today reported $5.2 million in revenue for the first quarter of fiscal year 2011 ended September 30, 2010.

27 Oct 2010

Baxa announces 2011 dates for courses at STAR Center training facility

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today announced the 2011 dates for its STAR (Skills Training, Academics and Resources) Center. Located at the Baxa global headquarters in Englewood CO, the STAR Center furthers best practice in health-system pharmacy operations. The ACPE-accredited 2011 curriculum offers participants hands-on training in a state-of-the-art cleanroom and pharmacy training facility.

27 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patients

A new British review of existing research suggests that while a newer type of radiation for the treatment of prostate cancer does not help patients live longer compared to an older type at least when similar doses are given it does appear to reduce gastrointestinal side effects.

27 Oct 2010

New International malaria research consortium to develop novel classes of antimalarials

Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

27 Oct 2010

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.

27 Oct 2010

CHORI hosts 2nd annual international Advanced Workshop on Sickle Cell Disease

Children's Hospital & Research Center Oakland is hosting the 2nd annual international Advanced Workshop on Sickle Cell Disease October 28 and 29. This impressive conference will bring together hematologists from Pakistan, Saudi Arabia, Mexico, Venezuela, Brazil, and beyond, and the premier sickle cell experts from the United States for a dialogue on research, comprehensive care, and new treatments and therapies.

27 Oct 2010

CHI releases new white paper on 510(k) review process

California Healthcare Institute today announced the release of a new white paper titled "Upcoming Changes to the 510(k) Process: New Approval Pathways and the Impact on Medical Device Development and Innovation." CHI is a non-profit public policy research and advocacy organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

27 Oct 2010

More research needed on impact of exercise on hypertensive patients

There are many good reasons to ensure sufficient exercise in everyday life. However, advising patients with increased blood pressure (hypertension) to exercise regularly is often regarded as a specific medical measure aiming to reduce the increased risk of late complications. But whether more exercise actually helps to avoid illnesses related to hypertension or at least delay their onset has been insufficiently investigated.

27 Oct 2010

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Dr Clare Scott from the Walter and Eliza Hall Institute in Melbourne, Australia, has been awarded a Victorian Cancer Agency (VCA) Clinical Fellowship to further research into an aggressive and highly lethal form of ovarian cancer.

27 Oct 2010

New guideline for using ESAs drugs in cancer patients

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

27 Oct 2010

Drugs News and Research

Causes, prevention, and management of inferior alveolar nerve injury during implant dentistry

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

More effective therapeutic exercises underutilized in treatment of chronic neck pain

InVivo Therapeutics completes reverse merger with InVivo

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

£600 million cancer drug fund for UK cancer patients

US FDA cracks down on importation of unapproved new drugs for personal use

Sharps Compliance first quarter retail billings increase 22% to record $1.9 million

Baxa announces 2011 dates for courses at STAR Center training facility

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patients

New International malaria research consortium to develop novel classes of antimalarials

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

CHORI hosts 2nd annual international Advanced Workshop on Sickle Cell Disease

CHI releases new white paper on 510(k) review process

More research needed on impact of exercise on hypertensive patients

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

New guideline for using ESAs drugs in cancer patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News